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Abstract
Transcription mediated by hypoxia-inducible factor (HIF-1) contributes to tumor angiogenesis and
metastasis but is also involved in activation of cell-death pathways and normal physiological
processes. Given the complexity of HIF-1 signaling, it could be advantageous to target a subset of
HIF-1 effectors rather than the entire pathway. We compare the genome-wide effects of three
molecules that each interfere with the HIF-1–DNA interaction: a polyamide targeted to the
hypoxia response element, small interfering RNA targeted to HIF-1α, and echinomycin, a DNA-
binding natural product with a similar but less specific sequence preference than the polyamide.
The polyamide affects a subset of hypoxia-induced genes consistent with its binding site
preferences. For comparison, HIF-1α siRNA and echinomycin each affect the expression of nearly
every gene induced by hypoxia. Remarkably, the total number of genes affected by either
polyamide or HIF-1α siRNA over a range of thresholds is comparable. The data show that
polyamides can be used to affect a subset of a pathway regulated by a transcription factor. In
addition, this study offers a unique comparison of three complementary approaches towards
exogenous control of endogenous gene expression.
Exogenous chemical and biological methods to control directly the expression of selected
endogenous genes could have broad implications for human medicine. Toward this goal, a
number of technological approaches are currently being investigated. Polydactyl zinc finger
proteins are a programmable class of DNA binding proteins capable of sequence-specific
binding (1,2). These designed proteins have been used to inhibit expression of target genes
(3), and transcriptional activator domain–zinc finger conjugates have been used to activate
expression of target genes (4). The RNA interference (RNAi) pathway can be used to
regulate gene expression at the post-transcriptional level (5). Small interfering RNA and
short-hairpin RNA molecules enlist cellular machinery to degrade selected messenger RNA
(mRNA) targets (6,7). RNAi technology has been highly effective in achieving potent and
specific knockdown of target mRNAs and is now widely used to probe target gene function
(8). However, bio-availability and delivery of zinc finger proteins and siRNA to targets in
humans could be an obstacle to their therapeutic application and continues to receive
considerable attention (8). Cell-permeable small molecules that modulate protein–protein or
protein–DNA interactions offer another approach to the control of endogenous gene
regulation. Screening small-molecule and natural-product libraries for a desired effect can
identify candidate molecules with high likelihoods of possessing drug-like bioavailability;
drawbacks include the need to screen anew for each target protein–protein or protein–DNA
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interaction. Polyamides containing N-methylimidazole (Im) and N-methylpyrrole (Py) are a
class of programmable DNA-binding small molecules previously used to disrupt protein–
DNA interactions in a sequence-specific manner in cell culture (9,10) (Figure 1).
Controlling the transcriptional activity of hypoxia inducible factor (HIF-1), a heterodimer of
HIF-1α and HIF-1β (ARNT), is a clinically relevant goal (11–14). HIF-1 is the principal
mediator of the adaptive cellular response to hypoxia (15). Under normoxic conditions,
HIF-1α is specifically hydroxylated by an iron-dependent proline hydroxylase, ubiquitinated
by the von Hippel–Lindau (VHL) tumor suppressor protein–ubiquitin ligase protein
complex, and degraded by the proteosome (16). Iron chelators, such as deferoxamine
(DFO), can be used to mimic hypoxia in cell culture (16). Through interaction with co-
activators p300/CBP, HIF-1 directly activates the expression of at least 100 genes involved
in cellular and tissue adaptation to hypoxia (13), including pro-angiogenic factors such as
vascular endothelial growth factor (VEGF), glycolytic enzymes, extracellular matrix
remodeling enzymes, and genes involved in both pro-survival and death pathways (11).
HIF-1 activation by the hypoxic microenvironment of solid tumors or by deactivating
mutations in VHL contributes to an aggressive phenotype of increased cell proliferation,
invasion, metastasis, and drug resistance (11). Given the complexity of HIF-1 signaling in
cellular survival and death pathways and its critical role in physiological processes in normal
tissues, it could be advantageous to target a subset of HIF-1 effectors rather than the entire
pathway (13).
In important proof of principle experiments, the introduction of siRNA against HIF-2α to
VHL−/− renal carcinoma cells was sufficient to abrogate tumor formation by these cells in
mice (17). Screening for small molecules capable of disrupting the HIF-1–p300 interaction
identified chetomin, a natural product that binds p300, which was shown to inhibit
expression of HIF-1 regulated genes and exhibit antitumor activity in a mouse model (18).
In an effort to inhibit directly HIF-1–DNA binding, a hairpin polyamide was designed to
bind the sequence 5′-ATACGT-3′ found in the VEGF hypoxia response element (HRE).
This polyamide bound its target site and prevented HIF-1–DNA binding in a sequence-
specific manner and inhibited hypoxia-induced expression of VEGF and several other HIF-1
regulated genes in cultured cells without the use of transfection agents (19,20). Melillo and
colleagues screened a library of small molecules for inhibition of HIF-1 mediated
transcription in a cell-based assay and identified the natural product echinomycin, a DNA-
binding bisintercalator (21). Echinomycin binds the four-base-pair sequence 5′-NCGN-3′
found in the consensus HRE 5′-NACGTG-3′ and inhibited expression of VEGF in cultured
cells (22).
To establish a benchmark of comparison for the global effects of polyamides, we compare
the genome-wide effects on U251 cells induced with DFO of a polyamide targeted to the
HRE sequence 5′-WTWCGW-3′, echinomycin, and siRNA targeted against HIF-1α. siRNA-
mediated destruction of HIF-1α mRNA establishes a maximum level of inhibition that can
be achieved for HIF-1 target genes through disruption of the HIF-1–HRE interaction. Nearly
all transcripts induced by DFO are inhibited by both HIF-1α siRNA and echinomycin.
Polyamide 1 inhibits only a subset of these genes and shows a preference for genes
containing HREs of the sequence 5′-(T/A)ACGTG-3′, consistent with this molecule’s
predicted binding preferences. Remarkably, the total number of genes affected by either
polyamide 1 or HIF-1α siRNA over a range of thresholds is comparable. We show that
HIF-1 occupancy at the HREs of two genes affected by polyamide 1 is reduced in the
presence of the polyamide, while HIF-1 occupancy at the HREs of one unaffected genes is
unchanged. We also show that a polyamide that binds a site immediately 5′ to the VEGF
HRE inhibits induced expression of VEGF but not of FMS-like tyrosine kinase 1 (FLT1,
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also known as vascular endothelial growth factor receptor), an HIF-1 target gene lacking this
flanking site.
RESULTS AND DISCUSSION
Binding of Polyamides 1, 2, 3 and Echinomycin at the VEGF and FLT1 HREs
Polyamide sequence specificity is programmed by side-by-side pairings of heterocyclic
amino acids in the minor groove of DNA: Im/Py distinguishes G·C from C·G; Py/Py binds
both A·T and T·A; and 3-chlorothiophene/Py (Ct/Py) prefers T·A at the N-terminus position
(23–25). Polyamide 1 and echinomycin are expected to bind at the VEGF HRE sequence 5′-
TACGTG-3′. Polyamide 2 is expected to bind the sequence 5′-AGTGCA-3′ immediately 5′
to the VEGF promoter HRE. HRE-mismatch control polyamide 3 targets the sequence 5′-
WGGWCW-3′, which is not found near the VEGF HRE. The DNA-binding affinities of 2,
3, and echinomycin for the VEGF HRE were measured by quantitative DNase I footprint
titrations using a 5′ 32P-labeled polymerase chain reaction (PCR) amplification product of
the plasmid pGL2-VEGF-Luc containing the VEGF HRE (Figure 2, panels a and b).
Polyamide 1 was previously found to bind the VEGF HRE (Ka = 2.6 (±0.4) × 1010 M−1)
(20). For ease of comparison, a footprinting gel of 1 is included. Polyamide 2 binds the site
5′-AGTGCA-3′ immediately 5′ to the VEGF HRE (Ka = 3.2 (±0.6) × 109 M−1).
Echinomycin binds the VEGF HRE (Ka = 8.4 (±2.1) × 106 M−1). Polyamide 3 binds the
VEGF HRE (Ka = 8.0 (±1.0) × 108 M−1) and ~35 base pairs 3′ of the HRE, most likely two
5′-WGWCW-3′ sites (Ka = 7.6 (±1.0) × 108 M−1).
The DNA-binding affinities of 1, 2, 3, and echinomycin for the HRE of FLT1 were
measured by quantitative DNase I footprint titrations using a 5′ 32P-labeled PCR
amplification product of the plasmid pCSJ-FLT1 (Figure 2, panels c and d). Although
formally targeted to the sequence 5′-WTWCGW-3′, polyamide 1 would be expected to bind
5′-CAACGT-3′, albeit with a moderate decrease in affinity (25). The sequence preference of
a Ct/Py pair for T·A is ~4-fold over A·T but 50-fold over a G·C (25). Polyamide 1 binds the
FLT1 HRE (Ka = 2.7 (±0.2) × 109 M−1). Polyamide 2 binds the FLT1 HRE (Ka = 2.2 (±0.8)
× 108 M−1). Echinomycin binds the FLT1 HRE (Ka = 2.9 (±0.7) × 107 M−1). Polyamide 3
does not bind the FLT1 HRE with a measurable Ka but was observed to bind a 5′-
AGACA-3′ site 16 base pairs 5′ to the FLT1 HRE (Ka = 2.7 (±0.4) × 109 M−1). These Ka
data are summarized in Supplementary Table 1.
Suppression of Induced VEGF and FLT1 Expression
HIF-1 induces VEGF expression by binding to the 5′-TACGTG-3′ HRE located ~950 base
pairs upstream of the transcription start site (26,27). The effect on induced VEGF expression
by siRNA silencing of HIF-1α mRNA establishes a theoretical maximum level of inhibition
through disruption of HIF-1–DNA binding. HIF-1α mRNA was reduced by approximately
95% in the presence of HIF-1α siRNA but was minimally affected by polyamides 1 or 2 or
echinomycin under induced conditions (Figure 3). A mismatch control siRNA did not
reduce HIF-1αmRNA. Polyamides 1 and 2 (1 μM) and HIF-1α siRNA had similar effects on
induced VEGF expression; treatment inhibited most of the increase in VEGF mRNA
following DFO treatment but not to levels below that observed for noninduced controls
(Figure 3, panel a). As previously reported, 100 nM echinomycin potently inhibits VEGF
expression to levels below the noninduced control (21). HRE-mismatch control polyamide
3, which binds the HRE with an affinity much reduced relative to that of 1, had a more
modest effect on VEGF mRNA levels. It is also possible that the modest but measurable
effect of polyamide 3 on VEGF expression could be due to interference with other protein–
DNA interactions elsewhere in the promoter or enhancer of VEGF or to secondary effects
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from direct effects on other genes. A mismatch control siRNA had a limited effect on VEGF
mRNA levels.
Induction of FLT1 (VEFG receptor type 1) is mediated by HIF-1 binding to the 5′-
AACGTG-3′ HRE in the FLT1 promoter (28). Polyamide 1 and HIF-1α siRNA both
inhibited FLT1 expression following DFO induction (Figure 3, panel b). Echinomycin
reduced FLT1 expression to below that of the noninduced control. Polyamides 2 and 3 had
minimal effect. A mismatch control siRNA also had a limited effect on FLT1 mRNA levels.
Given the relative binding affinities of polyamide 1 and echinomycin, it may be surprising
that 1 μM of polyamide 1 is necessary to inhibit VEGF and FLT1 expression comparably to
HIF-1α siRNA, whereas 100 nM echinomycin reduces their expression to sub-basal levels.
The structure of double-helical DNA is not greatly perturbed by minor groove-binding
hairpin polyamides (23); echinomycin–DNA binding causes local unwinding and
lengthening of the DNA helix, which might account for its greater potency in these
experiments (29,30). Polyamide–intercalator conjugates have been shown to unwind DNA
in a sequence-specific fashion and to improve the ability of a polyamide to inhibit binding of
several DNA-binding proteins in vitro (31,32). Attempts to use polyamide–intercalator
conjugates to target the VEGF HRE have not been successful because of poor nuclear
uptake.
The ability to target DNA sequences flanking critical protein–DNA binding sites while
maintaining productive inhibition of protein–DNA binding expands the repertoire of such
interactions amenable to inhibition by polyamides. In a similar approach, Kageyama et al.
showed that polyamides targeted to sequences flanking the VEGF HRE could inhibit VEGF
expression (33). Polyamides targeted to flanking sites have previously successfully inhibited
protein–DNA binding in the cases of TATA-binding protein and LEF-1 (34). It should be
noted that minor groove-binding polyamides and some major groove-binding proteins co-
occupy DNA sequences in some cases (35).
Microarray Analysis of Gene Expression
One potential limitation to the use of hairpin polyamides for gene regulation is binding site
size and specificity for match versus mismatch sites, which may result in prohibitively large
numbers of affected genes. To examine this, the global effects of polyamide treatment on
hypoxia-induced gene expression were measured using Affymetrix Human Genome U133
Plus 2.0 Arrays containing oligonucleotide sequences representing >50,000 transcripts. To
establish a benchmark for comparison, the effects of HIF-1α siRNA and echinomycin were
also measured. Experiments were conducted in triplicate, and gene expression levels
normalized to DFO-treated controls. Cells not treated with DFO were normalized to DFO-
treated controls.
Polyamide 1 (1 μM) affected expression of 2,284 transcripts by >2-fold (p ≤ 0.01) (Table 1).
At the same threshold, HIF-1α siRNA affected 3190 transcripts and echinomycin (100 nM)
affected 10,906. In all cases, a majority of affected genes were down-regulated. For
comparison, DFO treatment alone affected expression of 2142 transcripts (4.6% of
interrogated transcripts), with a majority up-regulated. Clustering analysis was performed to
identify similarities in the expression profiles between the different treatments (Figure 4).
The expression profile of cells treated with HIF-1 α siRNA is similar to that of cells not
treated with DFO under the conditions of the analysis; the expression profiles of
echinomycin-treated and polyamide-treated cells are less similar to each other and to the
other treatments. Analysis of transcripts affected by both 1 and HIF-1α siRNA shows that
395 and 150 transcripts are commonly down- and up-regulated, respectively, at least 2-fold
(p ≤ 0.01). A similar analysis of transcripts affected by both 1 and echinomycin shows that
731 and 112 transcripts are commonly down- and up-regulated, respectively. Analysis of
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transcripts affected by both siRNA and echinomycin shows that 1140 and 443 transcripts are
commonly down- and up-regulated, respectively. A side-by-side, genome-wide expression
analysis of fluorescein-tagged analogues of polyamides 1 and 3 in DFO-induced cells was
previously reported (19), and it was found that a majority of genes were uniquely affected
by each polyamide, with a number of genes commonly affected, under the conditions of the
experiments. It is not entirely unsurprising that there is some overlap in genes affected by
polyamides targeted to different DNA sequences, given that we do not have a full
understanding of all DNA sequences involved in the direct or indirect regulation of a given
gene.
We find that DFO induced the expression of a set of 297 transcripts by at least 4-fold (p ≤
0.01) (Figure 4, panel b). Of this set, 69 were inhibited by polyamide 1 by at least 2-fold (p
≤ 0.01). For comparison, HIF-1α siRNA inhibited 244, and echinomycin 263 of the 297
DFO-induced transcripts. It is not known what proportion of these affected transcripts are
direct HIF-1 targets. To examine more closely the effects of polyamide 1, HIF-1α siRNA,
and echinomycin on transcripts induced directly by HIF-1, we examined a limited set of 31
transcripts consisting of previously identified direct HIF-1 targets that were induced at least
1.5-fold (p ≤ 0.01) by DFO in this experiment (Figure 4, panel c) (28,36–45). Nearly all 31
transcripts in this set were down-regulated by HIF-1α siRNA. In most cases, the expression
was reduced to levels observed in cells untreated with DFO. Echinomycin treatment resulted
in down-regulation of all 31 transcripts. For some genes, including VEGF, expression was
reduced to levels far below those of the siRNA-treated cells and noninduced controls.
Polyamide 1 inhibited the expression of 14 of these but displayed minimal effect on the
others.
The HRE sequences for these genes, where known, are displayed in Table 2. Quantitative
real-time reverse transcriptase PCR (RT-PCR) was used to confirm the effects of
polyamides 1, 3, echinomycin, and siRNA treatments on these 11 genes. RT-PCR confirms
that siRNA and echinomycin reduced expression of all genes in this set. Polyamide 1
significantly affected four genes in this set. Polyamide 3 had a modest but measurable effect
on VEGF expression but little effect on the expression of all the others. Chromatin
immunoprecipitation was used to measure HIF-1 occupancy at the HREs of VEGF and
carbonic anhydrase IX (CA9), which were both affected by polyamide 1, and PGK1, which
was unaffected (Figure 5). HIF-1α occupancy at the VEGF HRE was decreased by HIF-1α
siRNA, echinomycin, and polyamide 1 but less so by treatment with HRE-mismatch
polyamide 3. HIF-1 occupancy at the CA9 locus was also decreased by HIF-1α siRNA,
echinomycin, and polyamide 1 but was unaffected by 3. HIF-1 occupancy at PGK1 was
markedly decreased by siRNA but minimally affected by polyamide 1 or 3. Surprisingly,
echinomycin did not appear to affect HIF-1 occupancy at this locus. It is interesting to note
that all of the genes affected by polyamide 1 displayed in Table 1 have HREs that fall within
the sequence 5′-(T/A)ACGTG-3′, consistent with the expected DNA binding preferences for
this molecule.
Conclusions and Significance
In this experiment, polyamide 1 (1 μM) affected expression of 2,284 transcripts by >2-fold
(p ≤0.01), which represents <5% of transcripts assayed. A search of the publicly available
human genome for the sequence 5′-WTWCGW-3′ finds 1,876,480 potential match sites for
polyamide 1. This corresponds to an average of 1 binding site every 1600 base pairs. The
proportion of these sites accessible to polyamide binding in the context of heterochromatin
in vivo is currently unknown. Additionally, data from in vitro transcription experiments
suggest that polyamides noncovalently bound within the coding region of a gene would not
interfere with RNA polymerase activity at that locus (34). It would thus not be surprising if a
significant fraction of polyamide–DNA binding events in a cell do not directly affect gene
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expression. In parallel to this, global analysis of transcription factor binding to chromatin in
vivo has shown occupancy at promoters and enhancers without associated changes in gene
expression at that locus (46).
Interestingly, polyamide 1 (1 μM) affected the expression of fewer genes than HIF-1α
siRNA under the conditions of the experiment. A direct comparison in genomic specificity
between polyamide and siRNA cannot be drawn from these limited data, because a large
proportion of the genes affected by siRNA are likely a result of silencing the target gene,
HIF-1α, rather than off-target effects involving post-transcriptional silencing of mRNA
using the RNAi pathway (47). If we eliminate from the total number of transcripts affected
by the HIF-1α siRNA (2-fold, p ≤ 0.01) all transcripts affected by treatment with DFO alone
(1.5-fold, p ≤ 0.01), we are left with 1523 affected transcripts. A similar treatment of the
data for polyamide 1 results in 1626 affected transcripts. It should also be noted that, for
most HIF-1 regulated genes affected by both polyamide and siRNA, inhibition by the
polyamide was more modest than by siRNA, suggesting incomplete abrogation of HIF-1
DNA binding by the polyamide. Polyamide 1 inhibited ~23% of the 297 transcripts induced
by DFO. For genes where the functional HRE has been identified, the effects of treatment
with polyamide 1 or echinomycin are, thus far, consistent with the expected binding
preferences of these molecules.
HIF-1 is frequently overactive in tumors, and a number of direct targets in the HIF-1
pathway have become points of clinical intervention (48). Bevacizumab, an anti-VEGF
antibody, and sorafenib and sunitinib, tyrosine kinase inhibitors with activity against the
VEGF receptors, have shown some promise in clinical trials as cancer therapeutics (49–51).
Echinomycin had been previously brought to the clinic as a cancer therapeutic in phase I and
II trials (52), based on observations that echinomycin exhibits potent antiproliferative effects
on several tumor-derived cell lines (52,53). However, survival benefit was not established
(52). In light of recent work by Melillo and colleagues, re-examination of the clinical use of
echinomycin in tumor types expected to be highly sensitive to HIF-1 activity may be
justified (21).
The induction of pro-angiogenic, proliferative, metastatic, and glycolytic genes by HIF-1 are
established as contributing to the cancer phenotype (11). Genes that promote cell death, such
as BNIP3 and NIX (BNIP3L), are also induced by hypoxia through HIF-1 (54). In this
sense, HIF-1 plays dual roles in the survival and death pathways of tumor cells (12). A
functional separation of these targets of HIF-1 at the level of HIF-1–DNA binding might
have clinical relevance (12). Given sufficient knowledge of the particular regulatory
sequences involved, one could, in principle, design a polyamide or cocktail of polyamides to
affect a selected subset of target genes in the HIF-1 pathway, making use of the
programmability of polyamide recognition for targeting particular HREs and flanking
sequences. The utility of polyamides as regulators of hypoxia-induced gene expression
awaits continued study in small-animal models of HIF-1 activity.
METHODS
Synthesis of Polyamides
Polyamides were synthesized by solid-phase methods on Kaiser oxime resin (Nova
Biochem), cleaved from the resin with 3,3′-diamino-N-methyl-dipro-pylamine, and purified
by reverse-phase HPLC (55). Isophthalic acid was activated with PyBOP (Nova Biochem)
and conjugated to the polyamides as previously described (20). Purity and identity of
polyamides assessed by HPLC, UV–visible spectroscopy, and MALDI TOFMS
(Supplementary Figure 1).
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Determination of DNA-Binding Affinities and Sequence Specificities
Quantitative DNase I footprint titration experiments were used to measure the binding
affinities of polyamides 1, 2, 3, and echinomycin on 5′ 32P-labeled fragments of pGL2-
VEGF-Luc and pCSJ-FLT1 containing promoter sequences containing the HREs of VEGF
and FLT1, respectively. Quantitative DNase I footprint titration experiments were conducted
as reported previously (56).
Measurement of Hypoxia-Induced Gene Expression
U251 cells were plated in 24-well plates at a density of 20 –30 × 103 cells per well (40–60 ×
103 cells mL−1) in Roswell Park Memorial Institute medium (ATCC) supplemented with
5% fetal bovine serum (Irvine Scientific). After 24 h, polyamides were added to the adhered
cells in cell media solutions at the appropriate concentration and incubated with the cells for
48 h. Hypoxic induction of gene expression was chemically induced by adding DFO to 300
μM for an additional 16 h. When appropriate, echinomycin was added 2 h prior to DFO
stimulation. Isolation of RNA and subsequent complementary DNA synthesis were as
previously described (19). When appropriate, HIF-1α siRNA (HIF-1α validated stealth
duplex, Invitrogen) or mismatch control siRNA with similar GC content (Invitrogen) was
transfected 48 h prior to RNA isolation. Transfection of siRNA was achieved using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s protocols. Quantitative real-
time RT-PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems) on
an ABI 7300 instrument. Target gene mRNA was measured relative to β-glucuronidase as
an endogenous control. Primers employed were VEGF, L 5′-
AGGGCAGAATCATCACGAAG-3′, R 5′-GGGTACTCC-TGGAAGATGTCC-3′; β-
glucuronidase, L 5′-CTCATTTGGAATTTTGCC-GATT-3′, R 5′-
CCGAGTGAAGATCCCCTTTTTA-3′; FLT1, L 5′-CAGC-
AACATGGGAAACAGAAT-3′, R 5′-TAGAGTCAGCCACAACCAAGG-3′.
Chromatin Immunoprecipitation
U251 cells were plated in 15-cm-diam plates and left to attach overnight. Media, time
course, DFO, polyamide, echinomycin, and siRNA treatments were as described above.
After the 16-h DFO treatment, cells were treated with 1% formaldehyde for 10 min.
Chromatin was isolated and sheared. HIF-1α antibodies (Novus Biologicals) were used to
immunoprecipitate HIF-1 bound DNA fragments. After cross-link reversal, PCRs using
primers targeted to the regions of interest were used to assess enrichment of bound
fragments as compared to mock-precipitated (no antibody) controls. PCRs were monitored
either using SYBR Green PCR Master Mix (Applied Biosystems) on an ABI 7300
instrument or directly visualized using gel electrophoresis. The following primers were
used: VEGF, L 5′-CCTTTGGGTTTTGCCAGA-3′, R 5′-CCAAGTTTGTGGAGCTGA-3′;
CA9, L 5′-AAAAGGGCGCTCTGTGAGT-3′, R 5′-GCTGACTGTGGGGT-GTCC-3′;
PGK1, L 5′-CCCCTAAGTCGGGAAGGTT-3′, R 5′-GTCCGTCTGCGAGGGTACTA-3′.
Analysis of Gene Expression with Oligonucleotide Microarrays
U251 cells were plated in 12-well plates at a density of 40–60 × 103 cells per well. Media,
time course, DFO, polyamide, echinomycin, and siRNA treatments were as described above.
RNA was isolated as previously described. Further sample preparation for microarray
experiments was carried out at the Millard and Muriel Jacobs Gene Expression Facility at
Caltech. Labeled mRNA was hybridized to Affymetrix Human 133 arrays according to
established protocols. Gene expression was analyzed using Resolver (Rosetta Biosoftware,
Seattle).
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Structures of molecules used in this study. a) Structures of polyamides 1–3 and
echinomycin. Imidazole, pyrrole, and chlorothiophene monomer units are represented by,
respectively, closed circles, open circles, and squares. b) Three approaches to inhibiting
gene expression induced by HIF-1: sequence-specific small-molecule binding to the HRE by
a polyamide or echinomycin and reduction in HIF-1α mRNA using siRNA.
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Figure 2.
Quantitative DNase I footprint titration experiments for polyamides 1–3 and echinomycin.
a) Illustration of pGL2-VEGF-Luc and partial sequence containing the VEGF HRE and
putative binding sites for polyamides 1, 2, and echinomycin. b) Quantitative DNase I
footprint titration experiments for polyamides 1, 2, 3, and echinomycin, E, on the 5′-end-
labeled PCR product of plasmid pGL2-VEGF-Luc. For polyamides 1, 2, and 3: lanes 1–11,
100 nM, 30 nM, 10 nM, 3 nM, 1 nM, 300 pM, 100 pM, 30 pM, 10 pM, 3 pM, and 1 pM
polyamide, respectively; lane 12, DNase I standard; lane 13, intact DNA; lane 14, A
reaction; lane 15, G reaction. For echinomycin, E: lanes 1–11, 10 μM, 3 μM, 1 μM, 300 nM,
100 nM, 30 nM, 10 nM, 3 nM, 1 nM, 300 pM, and 100 pM echinomycin, respectively; lanes
12–15 as above. Polyamide 1 and echinomycin have Ka = 2.6 (±0.4) × 1010 M−1 and Ka =
8.4 (±2.1) × 106 M−1, respectively, at the VEGF HRE. Polyamide 2 has Ka = 3.2 (±0.6) ×
109 M−1 for the site 5′-AGTGCA-3′ immediately 5′ to the VEGF HRE. Polyamide 3 has Ka
= 8.0 (±1.0) × 108 M−1 for the VEGF HRE. c) Illustration of pCSJ-FLT1 and partial
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sequence containing the FLT1 HRE and putative binding sites for polyamides 1 and
echinomycin. d) Quantitative DNase I footprint titration experiments for polyamides 1, 2, 3,
and echinomycin (E) on the 5′ end-labeled PCR product of plasmid pCSJ-FLT1. Lane
assignments for gels shown are as described for panel b. Polyamide 1 and echinomycin have
Ka = 2.7 (±0.2) × 109 M−1 and Ka = 2.9 (±0.7) × 107 M−1, respectively, at the FLT1 HRE.
Polyamide 2 has Ka = 2.2 (±0.8) × 108 at this site. Polyamide 3 does not bind the FLT1 HRE
with a measurable Ka.
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Figure 3.
Quantitative real-time PCR measurements. a) Induction of VEGF mRNA by the hypoxia
mimetic (DFO) measured by quantitative real-time PCR: HIF-1α siRNA, R; mismatch
control siRNA, R*; echinomycin (100 nM), E; and polyamides 1, 2, and 3 (1 μM).
Treatment with siRNA, 1, or 2 decreases VEGF mRNA levels to near-noninduced levels.
Echinomycin potently inhibits VEGF mRNA to below noninduced levels. Polyamide 3 has a
more modest effect. b) Induction of FLT1 mRNA by DFO measured by quantitative real-
time PCR: HIF-1α siRNA, R; mismatch control siRNA, R*; echinomycin (100 nM), E; and
polyamides 1, 2, and 3 (1 μM). The siRNA, echinomycin, and 1 decrease FLT1 mRNA
levels. Polyamides 2 and 3 have minimal or no effect. c) Measurement of HIF-1α mRNA by
quantitative real-time PCR: HIF-1α siRNA, R; mismatch control siRNA, R*; echinomycin
(100 nM), E; and polyamides 1 and 3 (1 μM). Treatment with siRNA decreases HIF-1α
mRNA by >95%.
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Figure 4.
Microarray analysis of gene expression. a) Divisive clustering analysis over all interrogated
transcripts for DFO-induced cells: HIF-1α siRNA, R; echinomycin (100 nM), E; and
polyamides 1 (1 μM). b) Agglomerative clustering analysis over all 297 transcripts induced
by DFO ≥4-fold (p ≤ 0.01). Of this transcript set, HIF-1α siRNA inhibited 244,
echinomycin inhibited 263, and polyamide 1 inhibited 69 by ≥2-fold (p ≤ 0.01). c) Effects
of the indicated treatments on a panel of genes previously characterized as direct targets of
HIF-1 and also induced by DFO at least 1.5-fold (p ≤ 0.01) in this experiment. Treatments
reported are an error-weighted average from three experiments. d) Venn diagrams
representing transcripts commonly down- and up-regulated (|fold-change| ≥ 2.0, p ≤ 0.01)
by 1 and HIF-1α siRNA, by 1 and echinomycin, and by HIF-1α siRNA and echinomycin.
Numbers inside the intersections represent transcripts affected by both treatments.
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Figure 5.
Chromatin immunoprecipitation at three HREs. a) Chromatin immunoprecipitation of
HIF-1α at the VEGF HRE following DFO treatment: HIF-1α siRNA, R; echinomycin (100
nM), E; and polyamides 1 and 3 (1 μM). Occupancy is decreased in the presence of R, E,
and 1 but only modestly affected by 3. b) Chromatin immunoprecipitation of HIF-1α at the
CA9 HRE. c) Chromatin immunoprecipitation of HIF-1α at the PGK1 HRE.
Nickols et al. Page 17
ACS Chem Biol. Author manuscript; available in PMC 2011 March 18.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Nickols et al. Page 18
TABLE 1
Number of transcripts affected (p ≤ 0.01)a
Treatment
None R E 1
No DFO With DFO With DFO With DFO
Up-regulated (fold change ≥ 2.0) 662 1380 3480 709
Down-regulated (fold change ≤ −2.0) 1480 1810 7426 1575
Up-regulated (fold change ≥ 4.0) 62 122 413 57
Down-regulated (fold change ≤ −4.0) 296 356 4133 336
a
R, HIF-1α siRNA; E, echinomycin; 1, polyamide.
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